COVID-19 Vaccination Rates in a Global HIV Cohort
Abstract Little is known regarding coronavirus disease 2019 (COVID-19) vaccination rates in people with HIV (PWH), a vulnerable population with significant morbidity from COVID-19. We assessed COVID-19 vaccination rates among 6952 PWH in the Randomized Trial to Prevent Vascular Events in HIV (REPRIE...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 2022-02, Vol.225 (4), p.603-607 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 607 |
|---|---|
| container_issue | 4 |
| container_start_page | 603 |
| container_title | The Journal of infectious diseases |
| container_volume | 225 |
| creator | Fulda, Evelynne S Fitch, Kathleen V Overton, Edgar T Zanni, Markella V Aberg, Judith A Currier, Judith S Lu, Michael T Malvestutto, Carlos Fichtenbaum, Carl J Martinez, Esteban Umbleja, Triin Douglas, Pamela S Ribaudo, Heather J Grinspoon, Steven K |
| description | Abstract
Little is known regarding coronavirus disease 2019 (COVID-19) vaccination rates in people with HIV (PWH), a vulnerable population with significant morbidity from COVID-19. We assessed COVID-19 vaccination rates among 6952 PWH in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) compared to region- and country-specific vaccination data. The global probability of COVID-19 vaccination through end of July 2021 was 55% among REPRIEVE participants with rates varying substantially by Global Burden of Disease (GBD) superregion. Among PWH, factors associated with COVID-19 vaccination included residence in high-income regions, age, white race, male sex, body mass index, and higher cardiovascular risk.
Clinical Trials Registration. NCT02344290. |
| doi_str_mv | 10.1093/infdis/jiab575 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8844595</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/infdis/jiab575</oup_id><sourcerecordid>2638558758</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-723c05e0feb15e47bb76bb4b9c54534956992ddd2248e98133422561abb5fa633</originalsourceid><addsrcrecordid>eNqFkc1LAzEQxYMoWqtXj7LgRQ9r8zWb5CJI1VoQBNFeQ7Kb1ZTtpm52Bf97t7QW9eJpDvObN_PmIXRC8CXBio18XRY-jubeWBCwgwYEmEizjLBdNMCY0pRIpQ7QYYxzjDFnmdhHB4wLxYmQA0TGj7PpTUpUMjN57mvT-lAnT6Z1MfF1YpJJFaypkvvpLBmHt9C0R2ivNFV0x5s6RC93t8_j-_ThcTIdXz-kOQfapoKyHIPDpbMEHBfWisxablUOHBhXkClFi6KglEunJGGMUwoZMdZCaTLGhuhqrbvs7MIVuavbxlR62fiFaT51MF7_7tT-Tb-GDy0l56CgFzjfCDThvXOx1Qsfc1dVpnahi5qCUkQozFa7zv6g89A1dW9P04xJAClA9tTlmsqbEGPjyu0xBOtVGnqdht6k0Q-c_rSwxb_f3wMXayB0y__EvgByHpND</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2638558758</pqid></control><display><type>article</type><title>COVID-19 Vaccination Rates in a Global HIV Cohort</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Fulda, Evelynne S ; Fitch, Kathleen V ; Overton, Edgar T ; Zanni, Markella V ; Aberg, Judith A ; Currier, Judith S ; Lu, Michael T ; Malvestutto, Carlos ; Fichtenbaum, Carl J ; Martinez, Esteban ; Umbleja, Triin ; Douglas, Pamela S ; Ribaudo, Heather J ; Grinspoon, Steven K</creator><creatorcontrib>Fulda, Evelynne S ; Fitch, Kathleen V ; Overton, Edgar T ; Zanni, Markella V ; Aberg, Judith A ; Currier, Judith S ; Lu, Michael T ; Malvestutto, Carlos ; Fichtenbaum, Carl J ; Martinez, Esteban ; Umbleja, Triin ; Douglas, Pamela S ; Ribaudo, Heather J ; Grinspoon, Steven K</creatorcontrib><description>Abstract
Little is known regarding coronavirus disease 2019 (COVID-19) vaccination rates in people with HIV (PWH), a vulnerable population with significant morbidity from COVID-19. We assessed COVID-19 vaccination rates among 6952 PWH in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) compared to region- and country-specific vaccination data. The global probability of COVID-19 vaccination through end of July 2021 was 55% among REPRIEVE participants with rates varying substantially by Global Burden of Disease (GBD) superregion. Among PWH, factors associated with COVID-19 vaccination included residence in high-income regions, age, white race, male sex, body mass index, and higher cardiovascular risk.
Clinical Trials Registration. NCT02344290.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/jiab575</identifier><identifier>PMID: 34794178</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Body mass index ; Cardiovascular diseases ; Clinical trials ; Coronaviruses ; COVID-19 ; COVID-19 - prevention & control ; COVID-19 vaccines ; COVID-19 Vaccines - administration & dosage ; HIV ; HIV Infections - therapy ; Human immunodeficiency virus ; Humans ; Immunization ; Major and Brief Reports ; Male ; Morbidity ; Randomized Controlled Trials as Topic ; Vaccination ; Vaccination - statistics & numerical data</subject><ispartof>The Journal of infectious diseases, 2022-02, Vol.225 (4), p.603-607</ispartof><rights>The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. 2021</rights><rights>The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-723c05e0feb15e47bb76bb4b9c54534956992ddd2248e98133422561abb5fa633</citedby><cites>FETCH-LOGICAL-c452t-723c05e0feb15e47bb76bb4b9c54534956992ddd2248e98133422561abb5fa633</cites><orcidid>0000-0003-4279-4737 ; 0000-0003-3156-2965</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,1578,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34794178$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fulda, Evelynne S</creatorcontrib><creatorcontrib>Fitch, Kathleen V</creatorcontrib><creatorcontrib>Overton, Edgar T</creatorcontrib><creatorcontrib>Zanni, Markella V</creatorcontrib><creatorcontrib>Aberg, Judith A</creatorcontrib><creatorcontrib>Currier, Judith S</creatorcontrib><creatorcontrib>Lu, Michael T</creatorcontrib><creatorcontrib>Malvestutto, Carlos</creatorcontrib><creatorcontrib>Fichtenbaum, Carl J</creatorcontrib><creatorcontrib>Martinez, Esteban</creatorcontrib><creatorcontrib>Umbleja, Triin</creatorcontrib><creatorcontrib>Douglas, Pamela S</creatorcontrib><creatorcontrib>Ribaudo, Heather J</creatorcontrib><creatorcontrib>Grinspoon, Steven K</creatorcontrib><title>COVID-19 Vaccination Rates in a Global HIV Cohort</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>Abstract
Little is known regarding coronavirus disease 2019 (COVID-19) vaccination rates in people with HIV (PWH), a vulnerable population with significant morbidity from COVID-19. We assessed COVID-19 vaccination rates among 6952 PWH in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) compared to region- and country-specific vaccination data. The global probability of COVID-19 vaccination through end of July 2021 was 55% among REPRIEVE participants with rates varying substantially by Global Burden of Disease (GBD) superregion. Among PWH, factors associated with COVID-19 vaccination included residence in high-income regions, age, white race, male sex, body mass index, and higher cardiovascular risk.
Clinical Trials Registration. NCT02344290.</description><subject>Body mass index</subject><subject>Cardiovascular diseases</subject><subject>Clinical trials</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 vaccines</subject><subject>COVID-19 Vaccines - administration & dosage</subject><subject>HIV</subject><subject>HIV Infections - therapy</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Immunization</subject><subject>Major and Brief Reports</subject><subject>Male</subject><subject>Morbidity</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Vaccination</subject><subject>Vaccination - statistics & numerical data</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1LAzEQxYMoWqtXj7LgRQ9r8zWb5CJI1VoQBNFeQ7Kb1ZTtpm52Bf97t7QW9eJpDvObN_PmIXRC8CXBio18XRY-jubeWBCwgwYEmEizjLBdNMCY0pRIpQ7QYYxzjDFnmdhHB4wLxYmQA0TGj7PpTUpUMjN57mvT-lAnT6Z1MfF1YpJJFaypkvvpLBmHt9C0R2ivNFV0x5s6RC93t8_j-_ThcTIdXz-kOQfapoKyHIPDpbMEHBfWisxablUOHBhXkClFi6KglEunJGGMUwoZMdZCaTLGhuhqrbvs7MIVuavbxlR62fiFaT51MF7_7tT-Tb-GDy0l56CgFzjfCDThvXOx1Qsfc1dVpnahi5qCUkQozFa7zv6g89A1dW9P04xJAClA9tTlmsqbEGPjyu0xBOtVGnqdht6k0Q-c_rSwxb_f3wMXayB0y__EvgByHpND</recordid><startdate>20220215</startdate><enddate>20220215</enddate><creator>Fulda, Evelynne S</creator><creator>Fitch, Kathleen V</creator><creator>Overton, Edgar T</creator><creator>Zanni, Markella V</creator><creator>Aberg, Judith A</creator><creator>Currier, Judith S</creator><creator>Lu, Michael T</creator><creator>Malvestutto, Carlos</creator><creator>Fichtenbaum, Carl J</creator><creator>Martinez, Esteban</creator><creator>Umbleja, Triin</creator><creator>Douglas, Pamela S</creator><creator>Ribaudo, Heather J</creator><creator>Grinspoon, Steven K</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4279-4737</orcidid><orcidid>https://orcid.org/0000-0003-3156-2965</orcidid></search><sort><creationdate>20220215</creationdate><title>COVID-19 Vaccination Rates in a Global HIV Cohort</title><author>Fulda, Evelynne S ; Fitch, Kathleen V ; Overton, Edgar T ; Zanni, Markella V ; Aberg, Judith A ; Currier, Judith S ; Lu, Michael T ; Malvestutto, Carlos ; Fichtenbaum, Carl J ; Martinez, Esteban ; Umbleja, Triin ; Douglas, Pamela S ; Ribaudo, Heather J ; Grinspoon, Steven K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-723c05e0feb15e47bb76bb4b9c54534956992ddd2248e98133422561abb5fa633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Body mass index</topic><topic>Cardiovascular diseases</topic><topic>Clinical trials</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 vaccines</topic><topic>COVID-19 Vaccines - administration & dosage</topic><topic>HIV</topic><topic>HIV Infections - therapy</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Immunization</topic><topic>Major and Brief Reports</topic><topic>Male</topic><topic>Morbidity</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Vaccination</topic><topic>Vaccination - statistics & numerical data</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fulda, Evelynne S</creatorcontrib><creatorcontrib>Fitch, Kathleen V</creatorcontrib><creatorcontrib>Overton, Edgar T</creatorcontrib><creatorcontrib>Zanni, Markella V</creatorcontrib><creatorcontrib>Aberg, Judith A</creatorcontrib><creatorcontrib>Currier, Judith S</creatorcontrib><creatorcontrib>Lu, Michael T</creatorcontrib><creatorcontrib>Malvestutto, Carlos</creatorcontrib><creatorcontrib>Fichtenbaum, Carl J</creatorcontrib><creatorcontrib>Martinez, Esteban</creatorcontrib><creatorcontrib>Umbleja, Triin</creatorcontrib><creatorcontrib>Douglas, Pamela S</creatorcontrib><creatorcontrib>Ribaudo, Heather J</creatorcontrib><creatorcontrib>Grinspoon, Steven K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fulda, Evelynne S</au><au>Fitch, Kathleen V</au><au>Overton, Edgar T</au><au>Zanni, Markella V</au><au>Aberg, Judith A</au><au>Currier, Judith S</au><au>Lu, Michael T</au><au>Malvestutto, Carlos</au><au>Fichtenbaum, Carl J</au><au>Martinez, Esteban</au><au>Umbleja, Triin</au><au>Douglas, Pamela S</au><au>Ribaudo, Heather J</au><au>Grinspoon, Steven K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COVID-19 Vaccination Rates in a Global HIV Cohort</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>2022-02-15</date><risdate>2022</risdate><volume>225</volume><issue>4</issue><spage>603</spage><epage>607</epage><pages>603-607</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><abstract>Abstract
Little is known regarding coronavirus disease 2019 (COVID-19) vaccination rates in people with HIV (PWH), a vulnerable population with significant morbidity from COVID-19. We assessed COVID-19 vaccination rates among 6952 PWH in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) compared to region- and country-specific vaccination data. The global probability of COVID-19 vaccination through end of July 2021 was 55% among REPRIEVE participants with rates varying substantially by Global Burden of Disease (GBD) superregion. Among PWH, factors associated with COVID-19 vaccination included residence in high-income regions, age, white race, male sex, body mass index, and higher cardiovascular risk.
Clinical Trials Registration. NCT02344290.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>34794178</pmid><doi>10.1093/infdis/jiab575</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0003-4279-4737</orcidid><orcidid>https://orcid.org/0000-0003-3156-2965</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 2022-02, Vol.225 (4), p.603-607 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8844595 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Alma/SFX Local Collection |
| subjects | Body mass index Cardiovascular diseases Clinical trials Coronaviruses COVID-19 COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - administration & dosage HIV HIV Infections - therapy Human immunodeficiency virus Humans Immunization Major and Brief Reports Male Morbidity Randomized Controlled Trials as Topic Vaccination Vaccination - statistics & numerical data |
| title | COVID-19 Vaccination Rates in a Global HIV Cohort |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T22%3A36%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COVID-19%20Vaccination%20Rates%20in%20a%20Global%20HIV%20Cohort&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Fulda,%20Evelynne%20S&rft.date=2022-02-15&rft.volume=225&rft.issue=4&rft.spage=603&rft.epage=607&rft.pages=603-607&rft.issn=0022-1899&rft.eissn=1537-6613&rft_id=info:doi/10.1093/infdis/jiab575&rft_dat=%3Cproquest_pubme%3E2638558758%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2638558758&rft_id=info:pmid/34794178&rft_oup_id=10.1093/infdis/jiab575&rfr_iscdi=true |